SLN (Silence Therapeutics) Ending Cash Position : $81.95 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics Ending Cash Position?

Silence Therapeutics's Ending Cash Position for the quarter that ended in Sep. 2024 was $81.95 Mil.

Silence Therapeutics's quarterly Ending Cash Position declined from Mar. 2024 ($143.65 Mil) to Jun. 2024 ($139.29 Mil) and declined from Jun. 2024 ($139.29 Mil) to Sep. 2024 ($81.95 Mil).

Silence Therapeutics's annual Ending Cash Position declined from Dec. 2021 ($97.79 Mil) to Dec. 2022 ($66.77 Mil) but then increased from Dec. 2022 ($66.77 Mil) to Dec. 2023 ($68.39 Mil).

Silence Therapeutics Ending Cash Position Historical Data

The historical data trend for Silence Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Ending Cash Position Chart

Silence Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

17.71

36.89

97.79

66.77

68.39

Silence Therapeutics Quarterly Data
	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Ending Cash Position	Get a 7-Day Free Trial															72.79	68.39	143.65	139.29	81.95

Silence Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Silence Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	69.388	+	-0.99400000000001
	=	68.39

Silence Therapeutics's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	144.817	+	-62.869
	=	81.95

Silence Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Silence Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (NAS:SLN) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

SLNCF:USA XRP2:Germany XRP2:Germany

Address

72 Hammersmith Road, London, GBR, W14 8TH

Website

https://www.silence-therapeutics.com

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.